Schizophrenia and Psychoses Archive

Efficacy of MIN-101 in Treating Negative Symptoms of Schizophrenia

Efficacy of MIN-101 in Treating Negative Symptoms of Schizophrenia

Researchers hope that in demonstrating the potential efficacy of MIN-101, they may improve the pharmacotherapy options available to patients with schizophrenia.

Early Intervention Services Superior to Treatment as Usual for Early-Phase Psychosis

Early Intervention Services Superior to Treatment as Usual for Early-Phase Psychosis

The superior benefit provided by early intervention services for schizophrenia could be cost-effective, and the researchers call for widespread implementation and funding of early intervention services in the United States and globally.

Gyrification-Based Connectomes Appear Promising for Predicting Transition to Psychosis

Gyrification-Based Connectomes Appear Promising for Predicting Transition to Psychosis

To date, there has been limited prognostic accuracy of clinical instruments in predicting the onset of psychosis and no reliable biological marker has been identified.

Risk of Breast Cancer May Be Higher in Women With Schizophrenia

Risk of Breast Cancer May Be Higher in Women With Schizophrenia

Researchers conducted a systematic literature review to identify cohort studies reporting the standardized incidence ratio for the risk of breast cancer in women with schizophrenia compared with the general population.

Substance Use Disorders Associated With Conversion From Schizotypal Disorder to Schizophrenia

Substance Use Disorders Associated With Conversion From Schizotypal Disorder to Schizophrenia

These data may be helpful in titrating care for those with schizotypal disorder and comorbid substance abuse disorders to mitigate the risk for conversion to schizophrenia.

Acadia Addresses Concerns Over Nuplazid Safety in Parkinson Disease Patients

Acadia Addresses Concerns Over Nuplazid Safety in Parkinson Disease Patients

Concerns over Nuplazid were initially voiced in a CNN article in early April which reported that the drug had been associated with over 700 deaths since its launch in March 2017.

Sleep Disturbances, Trauma Associated With Psychosis-Like Experiences

Sleep Disturbances, Trauma Associated With Psychosis-Like Experiences

These findings may be helpful in developing treatment strategies for patients with past trauma and sleep disturbances to attenuate the possibility of future psychosis-like experiences.

Childhood Insulin Resistance Associated With Later Psychosis

Childhood Insulin Resistance Associated With Later Psychosis

The authors advised clinicians to carefully consider which antipsychotics they prescribe their patients with metabolic dysfunction, as some are known to be diabetogenic.

Haloperidol Associated With Slight Increased Risk for Death in Acute Myocardial Infarction

Haloperidol Associated With Slight Increased Risk for Death in Acute Myocardial Infarction

These data may be useful to clinicians in considering the risks and benefits of prescribing haloperidol for patients with cardiac morbidity.

Violence in Schizophrenia Associated With Several Risk Factors at Diagnosis

Violence in Schizophrenia Associated With Several Risk Factors at Diagnosis

In patients with a history of pre-diagnostic violence, a history of non-violent offending in the 18-month period pre-diagnosis was the strongest predictor of future violence.

Exploring Brain Stimulation as a Treatment for Auditory Hallucinations in Schizophrenia

Exploring Brain Stimulation as a Treatment for Auditory Hallucinations in Schizophrenia

The authors pointed to a possible difference in the specific symptoms alleviated by different types of stimulation.

Recovery From First-Episode Psychosis More Likely in Those With Mania, Brief Psychosis Diagnoses

Recovery From First-Episode Psychosis More Likely in Those With Mania, Brief Psychosis Diagnoses

The early sustained recovery group was more likely to have a diagnosis other than schizophrenia, particularly mania or brief psychosis.

Negative Symptoms Increase Cardiovascular Risk in Schizophrenia

Negative Symptoms Increase Cardiovascular Risk in Schizophrenia

Although various clinical and psychosocial factors were associated with unhealthy lifestyle factors and higher risk for CVD, the strongest associations were with negative symptoms.

Improving Performance of Everyday Activities Is Critical in Schizophrenia

Improving Performance of Everyday Activities Is Critical in Schizophrenia

Treatment beyond antipsychotic drugs is needed for people with schizophrenia, as positive symptoms are a peripheral node in the network.

Independent Risk Pathways Shown for Diabetes and Obesity in Adults With Serious Mental Illness

Independent Risk Pathways Shown for Diabetes and Obesity in Adults With Serious Mental Illness

Given the high risk for metabolic disorder and type 2 diabetes, clinicians should select psychotropic medications carefully and monitor metabolic conditions regularly in their patients with serious mental illness.

Heavy Cigarette Smoking in Adolescence May Increase Risk for Psychosis

Heavy Cigarette Smoking in Adolescence May Increase Risk for Psychosis

Despite the recognition that early daily tobacco use likely increases the risk for later psychosis, investigation of the effect of covariates such as substance use, existing psychotic features, or parental/family factors was lacking in the literature.

CBT Plus Cognitive Remediation May Improve Vocational Outcomes in Schizophrenia

CBT Plus Cognitive Remediation May Improve Vocational Outcomes in Schizophrenia

These results suggest that CBT alone may be insufficient in enhancing work outcomes in patients with schizophrenia, despite its efficacy in treating other symptoms.

Adjunctive Raloxifene May Improve Psychotic Symptoms in Postmenopausal Women With Schizophrenia

Adjunctive Raloxifene May Improve Psychotic Symptoms in Postmenopausal Women With Schizophrenia

The meta-analysis showed raloxifene to be effective for positive symptoms, negative symptoms, and general psychopathology, with greatly homogeneous results.

Noninvasive Brain Stimulation May Improve Negative Schizophrenia Symptoms

Noninvasive Brain Stimulation May Improve Negative Schizophrenia Symptoms

The findings of this meta-analysis suggested that both repetitive transcranial magnetic stimulation and transcranial direct current stimulation were significantly more effective at improving negative symptoms than sham stimulation.

Infection in First Year Has Greatest Effect on IQ, Nonaffective Psychosis

Infection in First Year Has Greatest Effect on IQ, Nonaffective Psychosis

Investigators determined infections in the first year of life to be the "sensitive period" for risk of adult nonaffective psychosis.

Children Bullied by Sibling at Increased Risk of Developing a Psychotic Disorder

Children Bullied by Sibling at Increased Risk of Developing a Psychotic Disorder

Children who are involved in sibling bullying are at a higher risk of developing a psychotic disorder.

Plasma Autoantibodies Possible Biomarker for Schizophrenia

Plasma Autoantibodies Possible Biomarker for Schizophrenia

Investigators selected 15 genes associated with schizophrenia due to high expression in both brain tissue and B-lymphocyte cells.

Amisulpride May Be Most Effective Antipsychotic for Negative Symptoms in Schizophrenia

Amisulpride May Be Most Effective Antipsychotic for Negative Symptoms in Schizophrenia

There has been a question of whether antipsychotic medications are truly acting upon "primary" negative symptoms, or whether they are instead improving "secondary" negative symptoms via improvement in positive or depressive symptoms.

Cost-Effectiveness of Paliperidone Palmitate in Schizophrenia With Cardiometabolic Comorbidities

Cost-Effectiveness of Paliperidone Palmitate in Schizophrenia With Cardiometabolic Comorbidities

Although all-cause pharmacy costs were higher in the paliperidone palmitate group, adjusted all-cause medical costs were lower.

Virtual Reality Can Reduce Anxiety, Improve Social Interactions in Psychosis

Virtual Reality Can Reduce Anxiety, Improve Social Interactions in Psychosis

Use of virtual reality environments in which participants interact with computer-controlled situations or avatars enables a more fine-tuned approach to exposure in the context of cognitive behavioral therapy.

Addition of SSRIs to Antipsychotics Has Only Minor Impact on Metabolic Risk Factors

Addition of SSRIs to Antipsychotics Has Only Minor Impact on Metabolic Risk Factors

A combination of an SSRI and antipsychotics in a clinical setting most likely does not lead to a further deterioration of metabolic variables to a clinically significant degree.

Transcranial Direct Current Stimulation May Improve Motor Learning in Nonclinical Psychosis

Transcranial Direct Current Stimulation May Improve Motor Learning in Nonclinical Psychosis

tDCS may be an important tool for further improving our understanding of psychosis and designing targeted treatments.

First-Episode Schizophrenia: Searching for the Most Effective Atypical Antipsychotic

First-Episode Schizophrenia: Searching for the Most Effective Atypical Antipsychotic

Researchers examined which atypical antipsychotic was more effective and safe in first-episode drug-naive schizophrenia.

Examining the Benefit of Benzodiazepines for Psychosis-Associated Aggression, Agitation

Examining the Benefit of Benzodiazepines for Psychosis-Associated Aggression, Agitation

A meta-analysis of randomized, controlled trials compared the use of benzodiazepines alone or in combination with antipsychotic or antihistamine medications in patients experiencing acute psychotic illness.

Psychosis Associated With Increased Complications Following Total Joint Arthroplasty

Psychosis Associated With Increased Complications Following Total Joint Arthroplasty

Investigators seek the association between psychosis and complication risk after total joint arthroplasty.

Suppression of Auditory Stimuli Associated With Pathologic Symptoms of Schizophrenia

Suppression of Auditory Stimuli Associated With Pathologic Symptoms of Schizophrenia

P50 processing may inform researchers in the future development of interventions targeting cognitive impairment in schizophrenia.

Substance-Induced Psychosis Associated With Development of Schizophrenia, Bipolar Disorder

Substance-Induced Psychosis Associated With Development of Schizophrenia, Bipolar Disorder

All patients with a substance-induced psychosis should be offered follow-up.

Cognitive Insight Impairment May Precede Neurocognitive Decline in Schizophrenia

Cognitive Insight Impairment May Precede Neurocognitive Decline in Schizophrenia

This research suggests that interventions to improve cognitive insight may bolster neurocognition in schizophrenia.

Advanced Paternal Age Associated With Development of Schizophrenia, Mental Disorders

Advanced Paternal Age Associated With Development of Schizophrenia, Mental Disorders

Investigators seek the association between the risk of developing schizophrenia and advanced maternal and paternal age.

Subtle Gender Differences in Self-Perceived Symptoms of First-Episode Psychosis

Subtle Gender Differences in Self-Perceived Symptoms of First-Episode Psychosis

Gender differences may predict the types of symptoms and age of onset of schizophrenic psychosis.

Cardiovascular, Metabolic Biomarker Assessment in Early Psychosis

Cardiovascular, Metabolic Biomarker Assessment in Early Psychosis

Investigators assessed biomarkers for cardiovascular risk and protection in individuals with first-episode psychosis.

Effects of Social Recovery Therapy on Functional Outcomes in First-Episode Psychosis

Effects of Social Recovery Therapy on Functional Outcomes in First-Episode Psychosis

Investigators believe social recovery therapy may benefit individuals with complex comorbidities not motivated to participate in psychosocial interventions targeting functioning after first-episode psychosis.

Examining Metabolic Concerns Associated With Antipsychotics in Schizophrenia

Examining Metabolic Concerns Associated With Antipsychotics in Schizophrenia

Twelve antipsychotics, including olanzapine, ziprasidone, and lurasidone, were examined in a meta-analysis.

Examining the Potential of Neuroanatomical Imaging Signature for Schizophrenia Biomarkers

Examining the Potential of Neuroanatomical Imaging Signature for Schizophrenia Biomarkers

Technique validation suggested a robust generalizability of neuroanatomical imaging in schizophrenia.

AVATAR Therapy Reduces Auditory Verbal Hallucinations in Schizophrenia

AVATAR Therapy Reduces Auditory Verbal Hallucinations in Schizophrenia

AVATAR therapy significantly reduced the severity of hallucinations compared with supportive counseling.

Association of Schizophrenia-Related Polygenic-Risk Score Across Bipolar Disorder Subtypes

Association of Schizophrenia-Related Polygenic-Risk Score Across Bipolar Disorder Subtypes

A schizophrenia-related polygenic-risk score association gradient was identified across bipolar disorder phenotypes.

Psychotic Symptom Severity in BPAD Inversely Linked to Lithium Response

Psychotic Symptom Severity in BPAD Inversely Linked to Lithium Response

The severity of psychotic symptoms in patients with bipolar affective disorder correlated inversely with the response to lithium therapy.

Predictors of Aggression in Patients With Bipolar Disorder, Schizophrenia

Predictors of Aggression in Patients With Bipolar Disorder, Schizophrenia

Patients with schizophrenia-spectrum disorders had higher odds of being aggressive than people with bipolar disorder with a recent manic episode.

Readmission Risk for Schizophrenia Associated With Younger Age

Readmission Risk for Schizophrenia Associated With Younger Age

For patients with schizophrenia or schizoaffective disorder, younger age was significantly associated with an increased rate of readmission.

FDA Approves Schizophrenia Medication With Digital Ingestion Sensor

FDA Approves Schizophrenia Medication With Digital Ingestion Sensor

The ability to track ingestion of medications prescribed for mental illness may be useful for some patients.

Risk of Schizophrenia May Be Impacted by Inflammatory Biomarkers

Risk of Schizophrenia May Be Impacted by Inflammatory Biomarkers

The risk of developing schizophrenia may be impacted by specific inflammatory biomarkers.

Transcranial Stimulation Reduces Auditory Hallucinations in Schizophrenia

Transcranial Stimulation Reduces Auditory Hallucinations in Schizophrenia

Transcranial direct current stimulation might aid patients with schizophrenia who experience auditory hallucinations.

Lurasidone Reduces Agitation in Acute Exacerbation of Schizophrenia

Lurasidone Reduces Agitation in Acute Exacerbation of Schizophrenia

Lurasidone reduced agitation in patients with acute exacerbation of schizophrenia.

People With Schizophrenia More Likely to Die at a Younger Age

People With Schizophrenia More Likely to Die at a Younger Age

People with schizophrenia have a mortality rate 3 times higher than the general population, which may be linked to higher rates of smoking, alcohol consumption, poor diet, and lack of exercise in people with schizophrenia.

Quality of Diabetes Care Low Among Patients With Schizophrenia

Quality of Diabetes Care Low Among Patients With Schizophrenia

The quality of diabetes care was examined in patients with and without schizophrenia in a Danish nationwide cohort.

Long-Acting Injectable Antipsychotics Delay Schizophrenia Relapse

Long-Acting Injectable Antipsychotics Delay Schizophrenia Relapse

In patients with schizophrenia, long-acting injectable formulations of paliperidone palmitate delay relapse significantly after withdrawal.

Elevated Dopamine Synthesis Capacity Observed in Both Bipolar and Schizophrenia

Elevated Dopamine Synthesis Capacity Observed in Both Bipolar and Schizophrenia

Dopamine dysfunction underlies the pathoetiology of psychosis in both bipolar disorder and schizophrenia.

Predictors of Development of Early Onset Psychosis in Parkinson Disease

Predictors of Development of Early Onset Psychosis in Parkinson Disease

Researchers conducted a prospective case-control study to examine predictors of early and late-onset psychosis in Parkinson disease.

Persistent Negative Symptoms in First-Episode Psychosis Associated With Early Onset of Disease

Persistent Negative Symptoms in First-Episode Psychosis Associated With Early Onset of Disease

These findings suggest that there are critical periods of development associated with a higher risk of persistent negative symptoms.

New Performance-Based Tool Evaluates Cognitive Impact of Schizophrenia

New Performance-Based Tool Evaluates Cognitive Impact of Schizophrenia

In this study, 672 patients with schizophrenia were evaluated with the EPICOG-SCH brief cognitive battery.

Signs of Schizophrenia That Should Not Be Ignored

Signs of Schizophrenia That Should Not Be Ignored

Seven signs and symptoms might alert someone to the possible presentation of schizophrenia.

Diabetes Risk for Children, Young Adults on Second-Generation Antipsychotics

Diabetes Risk for Children, Young Adults on Second-Generation Antipsychotics

Type 2 diabetes is greater with second-generation antipsychotics than with non-second-generation antipsychotic psychotropic medications for patients aged 6 to 25 years.

FDA Issues Refusal to File Letter in Response to New Schizophrenia Drug

FDA Issues Refusal to File Letter in Response to New Schizophrenia Drug

The FDA issued a refusal to file letter for a new drug application.

Paliperidone Inadequate Responders May Benefit from Switch to Aripiprazole Lauroxil ER

Paliperidone Inadequate Responders May Benefit from Switch to Aripiprazole Lauroxil ER

Switching therapy to Aristada resulted in statistically significant and clinically meaningful improvement in schizophrenia symptoms.

Adjunctive Telmisartan's Effects on Symptoms of Schizophrenia

Adjunctive Telmisartan's Effects on Symptoms of Schizophrenia

Adding telmisartan to treatment with olanzapine or clozapine may improve symptoms of schizophrenia.

Why Do Antipsychotics Cause Weight Gain?

Why Do Antipsychotics Cause Weight Gain?

Researchers from the University of Texas Southwestern Medical Center have discovered the cellular receptor that causes weight gain from antipsychotic drugs.

Long-Term Cariprazine Safe, Tolerable for Schizophrenia

Long-Term Cariprazine Safe, Tolerable for Schizophrenia

Long-term treatment of schizophrenia with cariprazine was found to be both safe and well-tolerated.

Increased Psychotic Symptoms in Offspring of Patients With Schizophrenia

Increased Psychotic Symptoms in Offspring of Patients With Schizophrenia

Children and adolescent offspring of patients with schizophrenia demonstrate more attenuated psychotic symptoms.

Liraglutide Improves Cardiometabolic Disturbances in Schizophrenia Tx With Clozapine

Liraglutide Improves Cardiometabolic Disturbances in Schizophrenia Tx With Clozapine

Glucose tolerance and body mass index in patients with schizophrenia were improved by liraglutide.

Negative Symptoms In Schizophrenia Reduced By Novel Therapy

Negative Symptoms In Schizophrenia Reduced By Novel Therapy

Patients with schizophrenia in the MIN-101 trial demonstrated lower negative factor scores than a placebo group.

Memory Training Opportunities Exist for Patients With Schizophrenia

Memory Training Opportunities Exist for Patients With Schizophrenia

Impaired recollection could be a vulnerability marker for schizophrenia, whereas impaired social context memory could be a disease-related marker.

Long-acting Antipsychotics: Better Efficacy in Some Outcomes for Schizophrenia

Long-acting Antipsychotics: Better Efficacy in Some Outcomes for Schizophrenia

Schizophrenia treatment with long-acting injectable antipsychotic agents resulted in lower rehospitalization rates.

Clozapine as Causal Agent in Gastrointestinal Hypomotility Events

Clozapine as Causal Agent in Gastrointestinal Hypomotility Events

Clozapine-induced gastrointestinal hypomotility is a medical emergency that requires urgent attention.

Results for Patients With Schizophrenia Who Transition to PP3M

Results for Patients With Schizophrenia Who Transition to PP3M

A high percentage of patients were persistent and adherent to their PP3M treatment.

Clozapine Protects Patients With Tx-resistant Schizophrenia Against Self-harm

Clozapine Protects Patients With Tx-resistant Schizophrenia Against Self-harm

Clozapine might lower risk of self-harm for patients with treatment-resistant schizophrenia.

Mental Illness Leads to Higher Prevalence of Blood Viruses

Mental Illness Leads to Higher Prevalence of Blood Viruses

HIV, hepatitis B and hepatitis C are more common among patients with mental illnesses.

Psychosis Relapse Risk With Continued Cannabis Use and Poor Medication Adherence

Psychosis Relapse Risk With Continued Cannabis Use and Poor Medication Adherence

Interventions targeted at improving medication adherence might mitigate adverse effects of cannabis use on psychosis outcomes.

Long-Acting Injectable Antipsychotic May Reduce Costs, Increase Adherence in Schizophrenia

Long-Acting Injectable Antipsychotic May Reduce Costs, Increase Adherence in Schizophrenia

Long-acting injectables should be considered earlier in the treatment of schizophrenia.

Childhood Maltreatment Associated With Increased Risk of Psychosis in Ultra-High Risk Individuals

Childhood Maltreatment Associated With Increased Risk of Psychosis in Ultra-High Risk Individuals

Child maltreatment is significantly more prevalent in young individuals who present with UHR symptoms compared with controls.

Increases in Autonomic Function May Predict Auditory Hallucinations in SCZ

Increases in Autonomic Function May Predict Auditory Hallucinations in SCZ

Increases in autonomic function may predict the occurrence and severity of auditory hallucinations in patients with schizophrenia, suggesting a regulation of these experiences by the autonomic nervous system.

Diabetes Mellitus More Prevalent In Psychiatric Patients Than General Population

Diabetes Mellitus More Prevalent In Psychiatric Patients Than General Population

Diabetes mellitus (DM) appears to be more prevalent in the psychiatric setting than in the general population.

Schizophrenia Relapse Rate Lower With Injectable Versus Oral Antipsychotics

Schizophrenia Relapse Rate Lower With Injectable Versus Oral Antipsychotics

The risk for rehospitalization was 22% lower during treatment with long-acting injectable antipsychotic medications compared with treatment with equivalent oral formulations in the total cohort.

Schizophrenia Symptoms May Benefit From Specific Kind of Talk Therapy

Schizophrenia Symptoms May Benefit From Specific Kind of Talk Therapy

Schizophrenia patients may benefit from a a specific type of talk therapy, according to a new study from the University of Pennsylvania.

Concomitant Use of Antidepressants, Antipsychotics Linked to T2D Risk

Concomitant Use of Antidepressants, Antipsychotics Linked to T2D Risk

Concomitant SSRI/SNRI use was associated with an increased diabetes risk in AAP-treated young people.

Schizophrenia: Are There Any Effective Pharmacologic Combinations?

Schizophrenia: Are There Any Effective Pharmacologic Combinations?

There is currently no approved drug combination for treatment-resistant schizophrenia.

Cardiometabolic Outcomes in Schizophrenia Improved by Liraglutide

Cardiometabolic Outcomes in Schizophrenia Improved by Liraglutide

In patients with schizophrenia being treated with clozapine or olanzapine, liraglutide significantly improved glucose tolerance, body weight, and other cardiometabolic disturbances.

Schizophrenia Treatment Can Benefit From Electroconvulsive Therapy

Schizophrenia Treatment Can Benefit From Electroconvulsive Therapy

Electroconvulsive therapy can be a clinically effective treatment for patients with severe forms of schizophrenia.

Late Teen Emotional Stability Inversely Tied to Mental Illness

Late Teen Emotional Stability Inversely Tied to Mental Illness

Emotional stability assessed in late adolescence is inversely associated with serious mental illness.

Valbenazine Effective for Tardive Dyskinesia in Schizophrenia

Valbenazine Effective for Tardive Dyskinesia in Schizophrenia

Long-term valbenazine may be beneficial in managing tardive dyskinesia.

BMI In Schizophrenia Patients Associated With C-reactive Protein

BMI In Schizophrenia Patients Associated With C-reactive Protein

Body mass index in patients with schizophrenia is linked to C-reactive protein.

Metabolic, Endocrine Profiles Examined in Long-term Schizophrenia Therapy

Metabolic, Endocrine Profiles Examined in Long-term Schizophrenia Therapy

Schizophrenia outpatients were examined in this 52-week open-label extension trial.

Adolescents With Schizophrenia Prove Able to Tolerate Lurasidone

Adolescents With Schizophrenia Prove Able to Tolerate Lurasidone

Lurasidone is an atypical antipsychotic that has demonstrated efficacy in the treatment of schizophrenia in adolescents.

Antipsychotic Symptoms Persist for Patients Seeking Treatment

Antipsychotic Symptoms Persist for Patients Seeking Treatment

Dopamine-blocking antipsychotics are ineffective right from the onset of illness.

Psychotropic Medication Heightens Risk of Hip Fracture, MOF

Psychotropic Medication Heightens Risk of Hip Fracture, MOF

Mental disorders and psychotropic medication use are associated with an increased risk for fracture but are not fully captured by FRAX tool.

Antipsychotic Nonadherence Due to Social Stigma

Antipsychotic Nonadherence Due to Social Stigma

Schizophrenia was perceived as more distressful and with higher perceived social stigma than other disorders.

Schizophrenia Patients on Multiple Drugs Experience Cognitive Burden

Schizophrenia Patients on Multiple Drugs Experience Cognitive Burden

Scientists researched the association between multiple drug treatments for psychotic disorders and anticholinergic burden.

Antipsychotic Side Effect Treatment Gets FDA Approval

Antipsychotic Side Effect Treatment Gets FDA Approval

Ingrezza significantly and rapidly improved tardive dyskinesia symptoms compared to placebo, rmarking a tremendous breakthrough for patients suffering from TD.

Schizophrenia Risk Linked to Cannabis Use

Schizophrenia Risk Linked to Cannabis Use

Cannabis is the most widely misused illicit drug.

Schizophrenia Associated With Years of Life Lost

Schizophrenia Associated With Years of Life Lost

Schizophrenia was associated with 13 to 15 years of potential life lost.

Low Prenatal Weight Gain Linked to Offspring Psychosis Risk

Low Prenatal Weight Gain Linked to Offspring Psychosis Risk

The risk for offspring's development of psychosis is connected to maternal weight gain during pregnancy.

Antipsychotic Adherence Boosted by Financial Incentives

Antipsychotic Adherence Boosted by Financial Incentives

A trial at 3 mental health centers in The Netherlands revealed that patients with financial incentives have better compliance.

Schizophrenia Symptom Improvements and Adverse Effects

Schizophrenia Symptom Improvements and Adverse Effects

Participants in the risperidone group were generally more likely to achieve a significant clinical improvement in their mental state.

Schizophrenia Treatment Outcomes Favor Cariprazine Over Risperidone

Schizophrenia Treatment Outcomes Favor Cariprazine Over Risperidone

Cariprazine treatment led to greater improvement in the negative symptoms of schizophrenia than risperidone.

Schizophrenia Symptoms Reduced by Vitamin B

Adding high-dose B vitamins to traditional antipsychotic treatments reduces schizophrenia symptoms more than traditional treatments alone.

Sign Up for Free e-newsletters